Social anxiety disorder Mental and Behavioural Disorders
Conditions
Sponsors
University of Oxford
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients: 1. Social Anxiety Disorder is the main psychological problem, and the patient's priority to work on in therapy 2. Any gender, aged 18 years or above with no upper age limit. 3. Willingness to be allocated by chance to either iCT-SAD or NHS TT non-digital psychological treatment as usual (TAU) 4. Able to read and write in English 5. Access to the internet at home (or another safe location) and availability of tablet or laptop/computer, access to a mobile phone that can receive text messages Clinicians: 1. High Intensity CBT therapist or Psychological Well-Being practitioner working within a participating NHS TT service 2. Trained in the delivery of iCT-SAD 3. Willing to participate 4. Clinical capacity and managerial approval to participate
Exclusion criteria
Exclusion criteria: Patients: 1. Social Anxiety Inventory (SPIN) score below clinical caseness ( < 19) 2. Acute suicide risk 3. Substance dependence Clinicians: 1. No exclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Social anxiety symptoms measured with the Social Phobia Inventory (SPIN) completed at baseline, 22 weeks, 44 weeks and 66 weeks post-randomisation, and actual end of treatment if different from 22 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Reliable improvement and reliable recovery as defined in NHS TT manual based on cut-offs on the Social Phobia Inventory (SPIN) and Patient Health Questionnaire (PHQ-9) completed at 22 weeks after randomisation, and actual end of treatment if different from 22 weeks. 2. Depression symptoms measured with the Patient Health Questionnaire PHQ-9 completed at baseline, 22 weeks, 44 weeks and 66 weeks, and actual end of treatment if different from 22 weeks. 3. Anxiety symptoms measured with the Generalised Anxiety Disorder Questionnaire (GAD-7) completed at baseline, 22 weeks, 44 weeks and 66 weeks, and actual end of treatment if different from 22 weeks. 4. Interference with life due to mental health difficulties as measured with the Work and Social Adjustment Scale (WSAS) completed at baseline, 22 weeks, 44 weeks and 66 weeks, and actual end of treatment if different from 22 weeks. 5. Changes in employment and benefits status measured by patient demographics questionnaire at baseline, 22 weeks, 44 weeks and 66 weeks, and actual end of treatment if different from 22 weeks 6. Quality of life measured by the Recovering Quality of Life (ReQoL) at baseline, 22 weeks, 44 weeks and 66 weeks, and actual end of treatment if different from 22 weeks. 7. Therapist time involved in iCT-SAD and TAU as measured by number of sessions and their duration. 8. Cost effectiveness of iCT-SAD and TAU as measured by EuroQol EQ-5D-5L, Client Service Receipt Inventory, and iMTA Productivity Cost Questionnaire completed at baseline, 22 weeks, 44 weeks, 66 weeks, and actual end of treatment if different from 22 weeks. Process measures: 9. Treatment acceptability and patient satisfaction with treatment assessed with the NHS TT Patient Experience Questionnaire (PEQ), Acceptability Scale and interviews with some iCT-SAD patients at the end of treatment. 10. Credibility of treatment measured with the Borkovec and Nau Credibility scale after the second session with therapist. 11. Quality of therap | — |
Countries
England, United Kingdom
Contacts
Public ContactDonna Winston
Outcome results
None listed